Indian Journal of Cancer Home 

REVIEW ARTICLE
[View FULLTEXT] [Download PDF]
Year : 2019  |  Volume : 56  |  Issue : 4  |  Page : 293--296

Revisiting adjuvant ovarian suppression in premenopausal breast cancer patients

Waseem Abbas, Ranga Raju Rao 
 Department of Medical Oncology, Max Institute of Cancer Care, Shalimar Bagh, New Delhi, India

Correspondence Address:
Waseem Abbas
Department of Medical Oncology, Max Institute of Cancer Care, Shalimar Bagh, New Delhi
India

Adjuvant ovarian suppression, on addition to chemotherapy, reduces the risk of breast cancer in pre-menopausal women after surgery and adjuvant hormonal therapy. Suppression of Ovarian Function Trial (SOFT) and Tamoxifen and Exemestane Trial (TEXT) showed greater benefit with exemestane in high risk females in comparison to Tamoxifen. Ovarian Function Suppression (OFS) and exemestane became the standard of care, with 30% patients experiencing grade 3 and more side effects. Much higher benefit was seen in high risk group. But there are concerns about incomplete OFS (estrogen escape) with exemestane plus OFS. Updated analysis of TEXT AND SOFT showed better survival benefit with OFS plus Tamoxifen as compared to OFS plus exemestane. Overall survival is a better end point. Should preference be given to Tamoxifen over exemestane? Further research is required to get the final answer.


How to cite this article:
Abbas W, Rao RR. Revisiting adjuvant ovarian suppression in premenopausal breast cancer patients.Indian J Cancer 2019;56:293-296


How to cite this URL:
Abbas W, Rao RR. Revisiting adjuvant ovarian suppression in premenopausal breast cancer patients. Indian J Cancer [serial online] 2019 [cited 2019 Nov 15 ];56:293-296
Available from: http://www.indianjcancer.com/article.asp?issn=0019-509X;year=2019;volume=56;issue=4;spage=293;epage=296;aulast=Abbas;type=0